Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Wynne

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
HIV Research & Clinical Practice|December 16, 2021
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studiesMounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, et al.
The New England Journal of Medicine|November 8, 2013
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionSharon L Walmsley, Antonio Antela, Nathan Clumeck, et al.
Environment International|January 28, 2012
Policy, practice and decision making for zoonotic disease management: water and CryptosporidiumZoë Austin, Ruth E Alcock, Robert M Christley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO StudyJean van Wyk, Mounir Ait-Khaled, Jesus Santos, et al.
The Lancet. HIV|July 22, 2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b studyCatherine Orrell, Debbie P Hagins, Elena Belonosova, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 18, 2023
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical StudiesEva Fernvik, Juan Sierra Madero, Nuria Espinosa, et al.
Open Forum Infectious Diseases|July 31, 2023
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide-Based RegimensRachel L Batterham, Nuria Espinosa, Christine Katlama, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|June 1, 2011
Uncertainties in the governance of animal disease: an interdisciplinary framework for analysisRobert Fish, Zoe Austin, Robert Christley, et al.
Lancet (London, England)|January 10, 2018
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesJosep M Llibre, Chien-Ching Hung, Cynthia Brinson, et al.
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
HIV Research & Clinical Practice|December 16, 2021
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studiesMounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, et al.
The New England Journal of Medicine|November 8, 2013
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionSharon L Walmsley, Antonio Antela, Nathan Clumeck, et al.
Environment International|January 28, 2012
Policy, practice and decision making for zoonotic disease management: water and CryptosporidiumZoë Austin, Ruth E Alcock, Robert M Christley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO StudyJean van Wyk, Mounir Ait-Khaled, Jesus Santos, et al.
The Lancet. HIV|July 22, 2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b studyCatherine Orrell, Debbie P Hagins, Elena Belonosova, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 18, 2023
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical StudiesEva Fernvik, Juan Sierra Madero, Nuria Espinosa, et al.
Open Forum Infectious Diseases|July 31, 2023
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide-Based RegimensRachel L Batterham, Nuria Espinosa, Christine Katlama, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|June 1, 2011
Uncertainties in the governance of animal disease: an interdisciplinary framework for analysisRobert Fish, Zoe Austin, Robert Christley, et al.
Lancet (London, England)|January 10, 2018
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesJosep M Llibre, Chien-Ching Hung, Cynthia Brinson, et al.
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Pageof 8